Alterity Therapeutics Limited (ATHE)

Market Cap	10.36M
Revenue (ttm)	2.68M
Net Income (ttm)	-12.76M
Shares Out	5.32B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,869
Open	1.100
Previous Close	1.120
Day's Range	1.050 - 1.110
52-Week Range	1.010 - 5.410
Beta	0.68
Analysts	Buy
Price Target	4.00 (+280.95%)
Earnings Date	Dec 3, 2024

About ATHE

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: ATHE
• Website: https://alteritytherapeutics.com

Financial Performance

In 2024, Alterity Therapeutics's revenue was 4.02 million, an increase of 2.63% compared to the previous year's 3.92 million. Losses were -19.12 million, 38.5% more than in 2023.

Financial numbers in AUD

Analyst Forecast

According to one analyst, the rating for ATHE stock is "Buy" and the 12-month stock price forecast is $4.0.

Price Target

$4.0

(280.95% upside)

Analyst Consensus: Buy